Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 87 of 87 entries
Sorted by: Best Match Show Resources per page
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C.
PMID: 34653632
Ann Oncol. 2022 Jan;33(1):42-56. doi: 10.1016/j.annonc.2021.09.021. Epub 2021 Oct 13.

BACKGROUND: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established.PATIENTS AND METHODS: Fresh tumor and normal adjacent...

Cite
Federico L, McGrail DJ, Bentebibel SE, et al. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2021;33(1):42-56doi: 10.1016/j.annonc.2021.09.021.
Federico, L., McGrail, D. J., Bentebibel, S. E., Haymaker, C., Ravelli, A., Forget, M. A., Karpinets, T., Jiang, P., Reuben, A., Negrao, M. V., Li, J., Khairullah, R., Zhang, J., Weissferdt, A., Vaporciyan, A. A., Antonoff, M. B., Walsh, G., Lin, S. Y., Futreal, A., Wistuba, I., Roth, J., Byers, L. A., Gaudreau, P. O., Uraoka, N., Cruz, A. F., Dejima, H., Lazcano, R. N., Solis, L. M., Parra, E. R., Lee, J. J., Swisher, S., Cascone, T., Heymach, J. V., Zhang, J., Sepesi, B., Gibbons, D. L., & Bernatchez, C. (2022). Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 33(1), 42-56. https://doi.org/10.1016/j.annonc.2021.09.021
Federico, L, et al. "Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer." Annals of oncology : official journal of the European Society for Medical Oncology vol. 33,1 (2022): 42-56. doi: https://doi.org/10.1016/j.annonc.2021.09.021
Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2022 Jan;33(1):42-56. doi: 10.1016/j.annonc.2021.09.021. Epub 2021 Oct 13. PMID: 34653632.
Copy Download .nbib Format: NLM
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras-Gonzalez GM, Vining D, McElwaine-Johnn H, Wistuba II.
PMID: 33947698
Clin Cancer Res. 2021 Jul 01;27(13):3584-3594. doi: 10.1158/1078-0432.CCR-21-0238. Epub 2021 May 04.

PURPOSE: Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor.PATIENTS AND METHODS: KA2507 was characterized in HDAC...

Cite
Tsimberidou AM, Beer PA, Cartwright CA, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021;27(13):3584-3594doi: 10.1158/1078-0432.CCR-21-0238.
Tsimberidou, A. M., Beer, P. A., Cartwright, C. A., Haymaker, C., Vo, H. H., Kiany, S., Cecil, A. R. L., Dow, J., Haque, K., Silva, F. A., Coe, L., Berryman, H., Bone, E. A., Nogueras-Gonzalez, G. M., Vining, D., McElwaine-Johnn, H., & Wistuba, I. I. (2021). Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3584-3594. https://doi.org/10.1158/1078-0432.CCR-21-0238
Tsimberidou, Apostolia M, et al. "Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3584-3594. doi: https://doi.org/10.1158/1078-0432.CCR-21-0238
Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras-Gonzalez GM, Vining D, McElwaine-Johnn H, Wistuba II. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 Jul 01;27(13):3584-3594. doi: 10.1158/1078-0432.CCR-21-0238. Epub 2021 May 04. PMID: 33947698.
Copy Download .nbib Format: NLM
Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.

Scientific reports

Parra ER, Zhai J, Tamegnon A, Zhou N, Pandurengan RK, Barreto C, Jiang M, Rice DC, Creasy C, Vaporciyan AA, Hofstetter WL, Tsao AS, Wistuba II, Sepesi B, Haymaker C.
PMID: 33633208
Sci Rep. 2021 Feb 25;11(1):4530. doi: 10.1038/s41598-021-83858-x.

Immune profiling is becoming a vital tool for identifying predictive and prognostic markers for translational studies. The study of the tumor microenvironment (TME) in paraffin tumor tissues such as malignant pleural mesothelioma (MPM) could yield insights to actionable targets...

Cite
Parra ER, Zhai J, Tamegnon A, et al. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021;11(1):4530doi: 10.1038/s41598-021-83858-x.
Parra, E. R., Zhai, J., Tamegnon, A., Zhou, N., Pandurengan, R. K., Barreto, C., Jiang, M., Rice, D. C., Creasy, C., Vaporciyan, A. A., Hofstetter, W. L., Tsao, A. S., Wistuba, I. I., Sepesi, B., & Haymaker, C. (2021). Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Scientific reports, 11(1), 4530. https://doi.org/10.1038/s41598-021-83858-x
Parra, Edwin R, et al. "Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues." Scientific reports vol. 11,1 (2021): 4530. doi: https://doi.org/10.1038/s41598-021-83858-x
Parra ER, Zhai J, Tamegnon A, Zhou N, Pandurengan RK, Barreto C, Jiang M, Rice DC, Creasy C, Vaporciyan AA, Hofstetter WL, Tsao AS, Wistuba II, Sepesi B, Haymaker C. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021 Feb 25;11(1):4530. doi: 10.1038/s41598-021-83858-x. PMID: 33633208; PMCID: PMC7907283.
Copy Download .nbib Format: NLM
Showing 85 to 87 of 87 entries